[Studies on the fate of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FD-1), a new antitumor agent. I. Absorption, distribution, excretion and metabolism of FD-1 administered orally to rats (author's transl)].
D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D005663:Furans / Q000378:metabolism; D008297:Male; D011744:Pyrimidinones / Q000378:metabolism*; D051381:Rats; D013997:Time Factors; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D005663:Furans; D011744:Pyrimidinones